Recruiting PHASE2 INTERVENTIONAL 1-arm NCT05443646

Consolidation Serplulimab Following Concurrent Chemoradiotherapy for LS-SCLC Patients

A Phase II Study of Consolidation HLX10 (Serplulimab) Following Hypofractionated Radiotherapy With Concurrent Chemotherapy for Patients With Limited Stage Small Cell Lung Cancer

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Conditions Limited Stage Small Cell Lung Cancer

Interventions HLX10 Prophylactic Cranial Irradiation (PCI) hypofractionated radiotherapy

Updated 5 times since 2022 Last updated: May 4, 2024 Started: Sep 23, 2022 Primary completion: Jun 30, 2024 Completion: Jun 30, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05443646, this PHASE2 trial focuses on Limited Stage Small Cell Lung Cancer and remains actively recruiting participants. Sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, it has been updated 5 times since 2022, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Jun 2024 — Jul 2024 [monthly]

Recruiting PHASE2
Mar 2024 — Jun 2024 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Sep 2022 — Mar 2024 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Data source: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Jiamusi, China
• Taiyuan, China